Nasdaq · Healthcare
Fulgent Genetics, Inc. (FLGT)
As-reported financials and recent SEC filings for Fulgent Genetics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$322.7M
Net income
$-60.5M
Net margin
-18.8%
Diluted EPS
—
ROE
-5.5%
P/E (TTM)
—
Market cap
$566.9M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $322.7M | $283.5M | $289.2M | $619.0M | $992.6M |
| Gross profit | $130.9M | $107.2M | $104.5M | $366.9M | $777.1M |
| Operating income | $-91.1M | $-73.9M | $-195.5M | $178.5M | $676.0M |
| Net income | $-60.5M | $-42.7M | $-167.8M | $143.4M | $507.4M |
| Diluted EPS | — | — | — | — | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →1442026-06-02
View on EDGAR →8-K2026-06-02
View on EDGAR →42026-05-28
View on EDGAR →42026-05-28
View on EDGAR →Go deeper on FLGT
Search Fulgent Genetics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.